Am J Psychiatry 162:124-129, January 2005
© 2005 American Psychiatric Association
Olanzapine Treatment of Residual Positive and Negative Symptoms
Robert W. Buchanan, M.D.,
M. Patricia Ball, R.N.,
Elaine Weiner, M.D.,
Brian Kirkpatrick, M.D.,
James M. Gold, Ph.D.,
Robert P. McMahon, Ph.D., and
William T. Carpenter Jr., M.D.
OBJECTIVE: Olanzapine has been hypothesized to have superior efficacy in patients with treatment-resistant schizophrenia. The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive schizophrenia. METHOD: Sixty-three outpatients with schizophrenia who met retrospective and prospective criteria for either residual positive or residual negative symptoms entered a 16-week double-blind, parallel-groups comparison of olanzapine and haloperidol. RESULTS: There were no significant differences between the two drugs in their effect on positive or negative symptoms. There were no significant differences between the two treatment groups on measures of social and functional outcome. Olanzapine-treated patients had a significant reduction in extrapyramidal symptoms and subjective measures of stiffness and dry mouth, but the increases in systolic blood pressure and weight in olanzapine-treated patients were significantly greater than they were in haloperidol-treated patients. CONCLUSIONS: Olanzapine has limited differential benefit for either positive or negative symptoms in patients with treatment-resistant schizophrenia. Although olanzapine is associated with fewer extrapyramidal symptoms, other side effects may offset this benefit.
This article has been cited by other articles:
|
|
|
|
 
J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov
Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features
Schizophr Bull,
July 1, 2009;
35(4):
775 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kelly, E Weiner, M. Ball, R. McMahon, W. Carpenter, and R. Buchanan
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study
J Psychopharmacol,
June 1, 2009;
23(4):
436 - 441.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Focus,
January 1, 2008;
6(2):
212 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson
Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia
Psychiatr Serv,
July 1, 2007;
58(7):
983 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan
Persistent Negative Symptoms in Schizophrenia: An Overview
Schizophr Bull,
July 1, 2007;
33(4):
1013 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
August 1, 2005;
10(4):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. de HAAN and N. van BEVEREN
Olanzapine and Haloperidol for Residual Symptoms
Am J Psychiatry,
July 1, 2005;
162(7):
1392 - 1393.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
